deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT04978337

A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection (PRIMROSE)

A Phase 2b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection Who Are at High Risk for RSV-related Disease Progression

Sponsor: Janssen Research & Development, LLC

Conditions Respiratory Syncytial Virus
Interventions Placebo Rilematovir
Updated 14 times since 2021 Last updated: Aug 29, 2024 Started: Nov 17, 2021 Primary completion: Mar 31, 2022 Completion: Mar 31, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Janssen made the strategic decision to discontinue the PRIMROSE study. This decision is not based on any safety concerns.

Other terminated trials from Janssen Research & Development, LLC

More terminations from Janssen Research & Development, LLC

Listed as NCT04978337, this PHASE2 trial focuses on Respiratory Syncytial Virus and remains terminated or withdrawn. Sponsored by Janssen Research & Development, LLC, it has been updated 14 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Apr 2023 · 11 months · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jul 2024 · 14 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Sep 2025 · 11 months · monthly snapshot~Sep 2025 – present · 9 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Oct 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Sep 2024 — Oct 2024 [monthly]

    Terminated PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  5. May 2023 — Jul 2024 [monthly]

    Terminated PHASE2

▶ Show 9 earlier versions

  1. Apr 2023 — May 2023 [monthly]

    Terminated PHASE2

  2. May 2022 — Apr 2023 [monthly]

    Terminated PHASE2

    Status: Recruiting → Terminated

  3. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE2

  4. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE2

  5. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE2

  6. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE2

  7. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  8. Oct 2021 — Dec 2021 [monthly]

    Not Yet Recruiting PHASE2

  9. Sep 2021 — Oct 2021 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janssen Research & Development, LLC
Data source: Janssen Research & Development, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alicante, Spain , Bakersfield, United States , Bangkok, Thailand , Barcelona, Spain , Bialystok, Poland , Birmingham, United States , Bonn, Germany , Budapest, Hungary , Buenos Aires, Argentina , Canoga Park, United States and 66 more locations